India · Delayed Price · Currency is INR Laurus Labs Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw 23% revenue growth, margin expansion, and robust CDMO and generics performance, with strong outlook for FY 2027. Major CapEx is planned to support growth, and the business remains resilient to supply chain and concentration risks.
-
Q3 FY2026 saw robust revenue and margin growth, led by generics and CDMO, with strong ARV performance and continued investments in advanced manufacturing and R&D. Gross margins are expected to remain stable, and CapEx will exceed INR 1,000 crores annually.
-
Q2 FY26 saw robust revenue and margin growth, led by ARV and CDMO segments, with strong outlook and continued capacity investments. Gross margin neared 60%, EBITDA margin reached 26%, and CapEx remains focused on high-value segments. CDMO and generics both posted double-digit growth.
-
Q1 FY26 delivered 31% revenue growth, margin expansion, and strong CDMO momentum, with major capacity investments and a robust project pipeline supporting future growth. Gross margins are expected to remain high as CDMO share increases.
Fiscal Year 2025
-
FY2025 saw strong revenue and profit growth, driven by CDMO expansion, stable ARV sales, and robust operating margins. FY2026 is expected to deliver further growth, with increased CapEx focused on CDMO and no significant rise in debt. CDMO pipeline and big pharma partnerships continue to strengthen.
-
Q3 FY2025 saw strong revenue and margin growth, led by CDMO and formulations, with stable API performance. Strategic investments and capacity expansions are underway, with robust pipelines in CDMO and biotech. ARV revenues are expected to stabilize, and further growth is anticipated in FY2026.
-
Revenue remained flat at INR 1,224 crore in Q2 FY25, with strong CDMO growth offset by declines in ARV and oncology APIs. Gross margin held at 54-55%, EBITDA margin at 15%, and H2 is expected to drive growth and margin improvement, targeting 20% EBITDA for FY25.
-
Q1 FY25 saw flat revenue growth at INR 1,192 crore, strong gross margins at 55%, and subdued EBITDA margins due to low asset utilization and growth investments. CDMO and oncology APIs showed momentum, with H2 FY25 and FY26 expected to deliver stronger performance as new projects and capacities ramp up.